poliomyel
caus
polioviru
acut
infecti
diseas
may
lead
acut
flaccid
paralysi
children
enteroviru
famili
picornavirida
polioviru
three
serotyp
positivesens
singlestrand
rna
genom
compris
singl
open
read
frame
flank
region
tail
entri
host
cell
viru
employ
cellular
mechan
translat
polyprotein
polyprotein
initi
cleav
viral
proteas
protein
protein
cleav
capsid
protein
wherea
function
protein
viral
replic
live
attenu
oral
polioviru
vaccin
opv
made
attenu
strain
serv
primari
tool
erad
polio
worldwid
howev
vaccin
potenti
result
rare
advers
case
vaccineassoci
paralyt
poliomyel
vapp
circul
vaccinederiv
poliovirus
cvdpv
becom
major
concern
accord
report
global
annual
burden
vapp
estim
case
total
case
cvdpv
occur
world
last
even
highincom
countri
inactiv
poliomyel
vaccin
ipv
made
wild
strain
immun
schedul
vapp
risk
remain
foiadelli
et
al
report
first
vapp
case
immunodefici
infant
detect
albania
later
confirm
sabinlik
strain
clearli
phase
opv
vaccin
eventu
current
agenda
intern
commun
world
health
organ
set
goal
global
polio
erad
countri
still
use
live
vaccin
previou
trival
oral
polio
vaccin
topv
replac
bival
vaccin
bopv
routin
immun
program
along
introduct
least
one
dose
inactiv
polio
vaccin
ipv
given
wild
type
viru
must
handl
level
biocontain
laboratori
encourag
develop
novel
polio
vaccin
ipv
base
attenu
sabin
strain
sipv
first
sipv
combin
dtap
approv
japan
china
approv
standalon
sipv
follow
year
ongo
develop
tradit
ipv
deriv
wild
viru
strain
wipv
mostli
mahoney
saukett
type
clinic
evalu
sipv
vaccin
import
determin
crossprotect
vaccin
wild
viru
achiev
carri
neutral
assay
use
wildtyp
viru
strain
wt
viru
howev
wt
virusbas
neutral
assay
pose
challeng
opv
vaccin
produc
sinc
routin
oper
attenu
sabin
strain
addit
vaccin
evalu
clinic
trial
neutral
test
need
use
qualiti
control
ipv
ie
potenc
test
final
vaccin
bulk
rat
clearli
use
wt
viru
present
safeti
issu
oper
also
potenti
result
environment
contamin
inde
recommend
tight
biosafeti
measur
taken
prevent
leakag
live
therefor
would
desir
develop
new
assay
live
wt
viru
would
pseudovirus
viruslik
particl
replic
one
cycl
therefor
consid
minim
biosafeti
concern
recent
year
pseudovirus
use
place
wt
virus
neutral
assay
otherwis
must
conduct
biocontain
laboratori
virus
includ
sarscov
studi
three
pseudovirus
wild
mahoney
saukett
strain
construct
use
develop
neutral
test
place
wt
virus
report
new
assay
superior
tradit
assay
term
reproduc
sensit
could
viabl
altern
neutral
assay
potenc
analys
polio
vaccin
polio
pseudovirus
investig
studi
includ
mahoney
saukett
type
gener
transfect
vector
respect
capsid
protein
replicon
rna
shown
figur
cell
transfect
capsid
protein
vector
demonstr
appar
green
fluoresc
indic
success
express
protein
harvest
pseudovirus
concentr
time
ultrafiltr
express
analyz
use
western
blot
figur
clear
band
correspond
approxim
pseudoviru
sampl
across
differ
serotyp
lane
observ
well
posit
control
sipv
monoval
bulk
lane
howev
molecular
weight
pseudomahoney
protein
visibl
larger
posit
control
shown
western
blot
time
unabl
explain
observ
howev
given
gene
sequenc
verifi
antigen
confirm
differ
molecular
weight
like
due
cell
substrat
use
propag
viru
transmiss
electron
microscopi
analysi
reveal
morpholog
characterist
pseudoviru
particl
across
serotyp
resembl
true
viru
suggest
pseudovirus
success
packag
cell
figur
addit
conduct
separ
neutral
test
use
mous
sera
immun
monoval
vaccin
shown
figur
pseudovirus
neutral
correspond
serum
type
titrat
pseudovirus
rel
light
unit
rlu
valu
two
time
greater
valu
cell
control
consid
posit
base
criteria
viru
titer
mahoney
saukett
pseudovirus
prepar
studi
determin
respect
determin
serum
titer
pseudoviru
neutral
assay
base
endpoint
determin
specif
invers
highest
serum
dilut
inhibit
infect
first
determin
linear
rang
pseudoviru
infect
shown
figur
linear
respons
observ
use
virus
given
cell
growth
condit
chosen
amount
viru
use
pnt
expect
luciferas
activ
pseudovirusinfect
rd
cell
found
increas
time
shown
figur
rlu
valu
pseudovirus
mahoney
reach
plateau
took
pseudoviru
saukett
achiev
level
signal
time
remain
rel
stabl
declin
slightli
figur
therefor
chose
infect
final
rlu
readout
three
virus
establish
final
pseudoviru
neutral
test
procedur
serum
sampl
high
medium
low
titer
use
evalu
reproduc
establish
pnt
sampl
test
six
time
tabl
result
serum
titer
chang
found
within
twofold
rang
type
cv
valu
pseudomahoney
pseudosaukett
respect
indic
high
reproduc
neutral
test
base
pseudovirus
determin
correl
pnt
convent
neutral
assay
cnt
postvaccin
serum
sampl
phase
ii
clinic
trial
sipv
vaccin
select
take
account
distribut
antibodi
titer
within
group
see
section
compar
pnt
result
gener
cnt
wt
virus
use
spearman
correl
statist
analysi
shown
figur
statist
signific
strong
correl
pnt
cnt
demonstr
coeffici
viral
strain
r
p
mahoney
r
p
r
p
saukett
similar
valu
geometr
mean
titer
gmt
distribut
across
differ
immun
group
found
pnt
cnt
tabl
expect
gmt
valu
wipv
serum
group
higher
obtain
sipv
opv
group
given
antibodi
wipv
vaccin
group
match
wt
antigen
wherea
sipv
opv
vaccin
deriv
sabin
strain
differ
test
antigen
note
regardless
method
use
result
sipv
group
lower
two
group
sinc
sipv
group
sera
human
immun
high
middl
low
dose
data
present
group
serv
purpos
comparison
test
method
repres
true
valu
immunogen
group
interestingli
result
pnt
differ
immun
group
significantli
higher
cnt
pnt
method
present
may
sensit
tradit
method
accord
requir
outlin
tradit
wipv
vaccin
use
refer
vaccin
sipv
vaccin
clinic
result
separ
neutral
test
conduct
use
sabin
strain
wild
strain
evalu
immunogen
sinc
use
two
strain
would
allow
evalu
vaccineinduc
crossreact
accord
gapiii
requir
neutral
test
wild
strain
must
tightli
regul
conduct
level
biocontain
laboratori
studi
construct
three
type
pseudovirus
replac
wild
polioviru
strain
neutral
method
make
unnecessari
conduct
neutral
assay
laboratori
liu
et
al
develop
neutral
assay
base
pseudoviru
origin
sabin
strain
replicon
base
arita
et
al
develop
three
serotyp
pseudoviru
base
wildstrain
involv
replicon
base
mahoney
viru
firefli
luciferas
gene
instead
capsid
code
notabl
sabin
strain
safer
use
use
function
gene
attenu
strain
build
replicon
mahoney
saukett
pseudoviru
clone
found
structur
pseudoviru
produc
capsid
protein
differ
wild
strain
packag
replicon
correct
titer
meet
experiment
requir
employ
replicon
facilit
speedier
establish
differ
type
pnt
experi
differ
criteria
endpoint
calcul
report
pnt
assay
use
determin
antibodi
titer
report
rlu
threshold
valu
set
decreas
rlu
similar
criterion
use
studi
result
three
pseudovirus
highli
correl
cnt
method
correl
coeffici
greater
studi
gmt
detect
use
pnt
method
approxim
four
time
higher
detect
use
cnt
method
addit
laboratori
also
construct
pseudoviru
observ
similar
trend
unpublish
data
collect
result
suggest
pnt
establish
report
sensit
tradit
neutral
assay
could
accur
analysi
weakli
posit
antisera
exampl
sensit
neutral
assay
would
better
suit
potenc
test
sipv
vaccin
current
conduct
rat
usual
produc
weak
antibodi
respons
follow
immun
type
ii
sipv
vaccin
data
shown
note
sampl
size
increas
order
valid
pnt
assay
address
futur
studi
summari
develop
pseudovirusbas
neutral
assay
without
use
wt
viru
take
one
day
complet
assay
wherea
take
day
complet
tradit
assay
use
wt
viru
safe
sensit
assay
could
viabl
altern
approach
facilit
develop
polio
vaccin
human
rhabdomyosarcoma
rd
cell
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
gibco
code
penicillinstreptomycin
gibco
code
attenu
sabin
polioviru
strain
genbank
access
number
maintain
lab
wild
capsid
cdna
sequenc
mahoney
genbank
access
genbank
access
saukett
genbank
access
synthes
invitrogen
corpor
beij
china
plasmid
also
obtain
invitrogen
human
serum
sampl
phase
ii
clinic
trial
sipv
vaccin
kindli
provid
institut
medic
biolog
chines
academi
medic
scienc
serum
sampl
use
studi
sampl
obtain
immun
group
topv
wipv
sipv
respect
construct
pseudovirus
conduct
describ
arita
et
modif
capsid
protein
express
replicon
construct
brief
gene
capsid
protein
wildtyp
strain
polioviru
mahoney
saukett
fuse
egfp
use
primer
see
tabl
facilit
detect
protein
express
also
ad
cleavag
site
proteas
two
sequenc
figur
express
protein
cleav
capsid
protein
egfp
also
remov
appropri
pseudovir
packag
target
gene
sequenc
carri
restrict
site
vector
invitrogen
code
infus
clone
method
adopt
construct
express
purpos
primer
see
tabl
design
ligat
respect
fusion
protein
vector
final
recombin
plasmid
verifi
dna
sequenc
subsequ
use
transfect
cell
express
capsid
protein
pseudoviru
packag
unlik
previou
studi
pseudovir
packag
replicon
use
studi
viral
genom
purpos
fragment
genom
replac
luciferas
gene
insert
restrict
site
luciferas
fragment
figur
brief
viral
genom
rna
extract
transcrib
cdna
sequenc
ie
end
genom
amplifi
pcr
ligat
clone
vector
respect
takara
code
two
plasmid
use
templat
follow
construct
luciferas
gene
fuse
pcr
use
primer
fluciferaseolrluciferaseol
similarli
primer
use
creat
luciferas
fusion
fragment
fragment
clone
pgemt
easi
vector
promotor
transcript
vitro
primer
freplicon
rrepliconpolya
poli
tail
introduc
fusion
product
ensur
structur
primer
use
also
shown
tabl
construct
replicon
dna
vector
linear
sali
restrict
enzym
digest
neb
code
replicon
rna
obtain
vitro
use
ribomax
largescal
rna
product
kit
promega
code
figur
result
replicon
rna
purifi
isopropanol
precipit
store
subsequ
transfect
pseudovir
packag
perform
sequenti
transfect
capsid
protein
express
vector
replicon
rna
cell
figur
brief
cell
digest
plate
sixwel
plate
densiti
cellswel
incub
vector
transfect
accord
manual
transfect
reagent
invitrogen
code
express
fusion
protein
monitor
fluoresc
microscop
transfect
follow
transfect
replicon
rna
later
cell
cultur
subject
two
freezethaw
cycl
subsequ
harvest
cellular
debri
remov
centrifug
g
min
supernat
filter
use
membran
pall
code
eventu
store
prior
use
harvest
pseudoviru
supernat
load
onto
trisglycin
gel
separ
sdspage
protein
band
transfer
onto
nitrocellulos
membran
millipor
code
subsequ
block
overnight
pbst
buffer
contain
sigma
code
skim
milk
bd
code
membran
incub
polyclon
rabbit
antimahoney
saukett
antibodi
wash
pbst
time
membran
incub
horseradish
peroxidas
hrp
conjug
antirabbit
igg
sigma
code
membran
wash
pbst
time
ad
enhanc
chemiluminesc
ecl
reagent
ge
item
substrat
expos
visual
chemiluminesc
imag
chemi
docit
hr
imag
system
uvp
america
confirm
type
specif
pseudovirus
use
measur
neutral
titer
mous
sera
prepar
immun
type
vaccin
bulk
briefli
serum
sampl
first
inactiv
serial
dilut
twofold
fluoresc
detect
plate
equal
volum
pseudoviru
contain
ad
incub
follow
addit
rd
cell
suspens
densiti
supernat
discard
follow
incub
premix
chromogen
substrat
contain
cell
lysi
buffer
luciferas
substrat
ratio
ad
well
plate
briefli
shaken
mix
place
room
temperatur
min
rlu
detect
pseudoviru
infect
rate
differ
dilut
point
calcul
compar
total
ml
sampl
collect
pseudoviru
type
ultracentrifug
optima
xp
beckman
coulter
america
g
h
supernat
discard
wherea
pellet
resuspend
pb
sampl
ad
copper
mesh
fix
osmium
tetroxid
pseudovirion
observ
transmiss
electron
microscop
jeol
datum
america
acceler
voltag
magnif
titrat
pseudovirus
perform
pseudovirus
collect
serial
dilut
fivefold
column
plate
costar
code
eight
well
per
dilut
digest
rd
cell
ad
densiti
well
mix
incub
total
supernat
discard
well
brightglo
luciferas
assay
reagent
promega
code
ad
well
plate
left
dark
min
room
temperatur
afterward
mixtur
transfer
test
plate
costar
item
chemiluminesc
detect
navig
promega
america
rlu
three
time
higher
blank
control
consid
posit
viru
titer
determin
use
spearmankarb
method
use
pseudovirus
infect
rd
cell
seed
earlier
plate
addit
incub
rlu
lg
scale
determin
plot
challeng
amount
titer
valu
differ
pseudoviru
amount
convert
lg
form
order
better
observ
linear
relationship
final
challeng
amount
pseudoviru
neutral
test
pnt
chosen
demonstr
linear
regress
time
point
determin
pseudovirus
ad
volum
rd
cell
incub
time
rlu
valu
reach
plateau
taken
final
neutral
test
final
pseudovir
neutral
test
procedur
optim
base
amount
pseudoviru
time
rlu
serum
sampl
first
inactiv
dilut
eightfold
neutral
test
serial
dilut
twofold
fluoresc
detect
plate
afterward
equal
volum
pseudoviru
contain
ad
incub
follow
addit
rd
cell
suspens
densiti
plate
contain
eight
well
cell
pseudoviru
control
respect
supernat
discard
follow
incub
premix
chromogen
substrat
contain
cell
lysi
buffer
luciferas
substrat
ratio
ad
well
plate
briefli
shaken
mix
place
room
temperatur
min
rlu
detect
pseudoviru
infect
rate
calcul
dilut
infect
rate
rluserum
rlucellcontrol
rlupseudovir
rlucel
control
highest
serum
dilut
show
infect
rate
less
determin
neutral
antibodi
titer
addit
control
viral
back
titrat
control
serum
qualiti
control
also
includ
run
test
assess
reproduc
pseudovir
neutral
test
select
sera
high
medium
low
titer
assay
develop
sampl
test
six
time
reproduc
pnt
assay
evalu
calcul
coeffici
variat
use
graph
pad
prism
result
cnt
obtain
cdc
laboratori
unit
state
neutral
antibodi
titer
mahoney
saukett
strain
determin
neutral
antibodi
test
perform
use
standard
briefli
dilut
serum
mix
equal
volum
medium
contain
polioviru
plate
incub
follow
addit
cell
suspens
cell
incub
day
cytopath
effect
viral
infect
examin
serum
antibodi
titer
highest
dilut
serum
protect
cultur
viral
challeng
use
reedmuench
method
result
gener
pnt
compar
obtain
cnt
spearman
correl
analysi
perform
use
graphpad
softwar
potenti
conflict
interest
report
author
